Peptide useful for the transport of molecules through cell barriers

Patent metadata

Field	Value
Publication number	US-12466854-B2
Application number	US-202318850224-A
Country	US
Kind code	B2
Filing date	Apr 11, 2023
Priority date	Apr 11, 2022
Publication date	Nov 11, 2025
Grant date	Nov 11, 2025

Abstract

A new peptide and its use as a vector for the transport of molecules after conjugation through cellular barriers for the diagnosis, prognosis or treatment of pathologies of the central nervous system (CNS).

First claim

The invention claimed is:

1 . A peptide comprising a peptide of amino acid sequence SEQ ID NO 1.

2 . A peptide conjugate comprising the peptide according to claim 1 , wherein the peptide is covalently linked to a molecule of interest, directly or via a linker.

3 . The peptide conjugate according to claim 2 , wherein the linker is composed of 1 to 6 amino acids.

4 . The peptide conjugate according to claim 2 , wherein the molecule of interest is chosen from the group consisting of an antibody, a DNA, an RNA, a peptide, and a drug.

5 . The peptide conjugate according to claim 4 , wherein the antibody is a single domain antibody.

6 . The peptide conjugate according to claim 5 , wherein the single domain antibody is an anti-Tau single domain antibody that comprises the amino acid sequence SEQ ID NO: 3.

7 . The peptide conjugate according to claim 6 comprising the amino acid sequence SEQ ID NO: 4.

8 . A nucleic acid sequence encoding the peptide according to claim 1 , wherein the nucleic acid sequence further encodes a molecule of interest, and wherein the peptide is covalently linked to the molecule of interest directly or via a linker further encoded by the nucleic acid sequence.

9 . An expression vector comprising a nucleic acid sequence as defined in claim 8 .

10 . A method comprising
diagnosing, prognosing, or treating a pathology of the central nervous system (CNS) with the peptide conjugate according to claim 2 .

11 . The method according to claim 10 , wherein the CNS pathology is chosen from the group consisting of brain tumors, cerebrovascular accidents (CVA), Huntington's disease, multiple sclerosis and tauopathies.

12 . The method according to claim 11 , wherein the tauopathies are chosen from the group consisting of Parkinson's disease, Pick's disease, and Alzheimer's disease.

Assignees

• Univ Grenoble Alpes
• Inst Nat Sante Rech Med

Inventors

• Lombardi Charlotte
• Moulin Marcelle
• Ghezzi Catherine

Classifications

• C07K2319/01

  containing a localisation/targetting motif · CPC title

• C07K2317/569

  Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody® · CPC title

• C07K16/18

  against material from animals or humans · CPC title

• C07K7/08

  having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title